Uncategorized

#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts

#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts

Published

2 days ago

on

The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed, showed that a targeted “pan-RAS” drug doubled the survival time for patients whose pancreatic cancer has returned or stopped …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version